Insights into the success and failure of systemic therapy for hepatocellular carcinoma

Area of Science:

• Hepatocellular carcinoma (HCC) research
• Clinical trial design in oncology
• Systemic cancer therapy

Background:

• Sorafenib's approval marked a shift in hepatocellular carcinoma (HCC) treatment, introducing targeted therapy concepts.
• Despite advances, HCC prognosis remains challenging, necessitating improved systemic treatments.
• Clinical trials in HCC face significant hurdles including patient selection and endpoint determination.

Purpose of the Study:

• To review recent advances in systemic therapy for hepatocellular carcinoma (HCC).
• To critically evaluate clinical trial designs in HCC, identifying challenges and opportunities.
• To emphasize the importance of learning from past trial outcomes for future research.

Main Methods:

• Comprehensive review of systemic agents and immunotherapies for HCC.
• Analysis of common obstacles in HCC clinical trial design.
• Evaluation of current criteria for assessing treatment response and progression.

Main Results:

• The incorporation of novel targeted agents and immunotherapies has significantly boosted systemic treatment options for HCC.
• Existing criteria for treatment response and progression in HCC trials may hinder accurate clinical judgment.
• Past clinical trial failures and successes offer crucial lessons for optimizing future HCC research.

Conclusions:

• Future clinical trials for hepatocellular carcinoma (HCC) must incorporate lessons learned from previous research to improve efficacy.
• Refined strategies for patient selection, prognostic assessment, and endpoint definition are crucial for advancing HCC treatment.
• Continued development and strategic trial design are essential to overcome the challenges in managing advanced HCC.